Clinical Trials Logo

Clinical Trial Summary

This Phase 2 clinical study is designed as a multicenter, randomized, blinded, controlled study to evaluate the safety and efficacy of NV-101 in approximately 150 children 4 to 11 years of age. NV-101 or sham injection is administered at the completion of a dental procedure requiring local anesthesia with 2% lidocaine with 1:100,000 epinephrine. The dental procedure(s) shall be performed in a single quadrant of the mouth and include cavity preparation, restoration/filling, teeth cleaning (non-surgical scaling and/or root planing), or crowns.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00309322
Study type Interventional
Source Novalar Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 2
Start date March 2006
Completion date August 2006

See also
  Status Clinical Trial Phase
Withdrawn NCT03318952 - Articaine vs Lidocaine for Pediatric Dental Procedures Phase 4
Completed NCT04317508 - Using Anesthetic Gel Patches to Reduce Pain of Palatal Injection Phase 1/Phase 2
Completed NCT00363207 - Behavior of Children Related to Numbness After Dental Local Anesthesia N/A
Completed NCT00309361 - Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures Phase 3
Completed NCT00309335 - Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures Phase 3
Completed NCT05839093 - Anesthesia Techniques in Symptomatic Mandibular Molars With Irreversible Pulpitis N/A
Completed NCT05423392 - Efficacy of 4% Articaine Terminal Anesthesia in the Lateral Jaw Region in Children N/A